Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 6/20 | 0.40 |
| ▸ | FGFR3 | P22607 | 9/20 | 0.38 |
| ▸ | FGFR1 | P11362 | 7/20 | 0.38 |
| ▸ | FGFR2 | P21802 | 7/20 | 0.38 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | F2 | P00734 | 1/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | FGFR4 | P22455 | 4/20 | 0.37 |
| ▸ | KDR | P35968 | 2/20 | 0.36 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.36 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.35 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL173298 | 0.91 | BRD4 (0.38) | METFGFR3FGFR1FGFR2PDE10A | |
| SCHEMBL368129 | 0.91 | MIF (0.40) | METFGFR3FGFR1FGFR2PDE10A | |
| SCHEMBL178094 | 0.90 | MET (0.44) | METFGFR3FGFR1 | |
| SCHEMBL360598 | 0.90 | PDE10A (0.38) | METFGFR3FGFR1PDE10A | |
| SCHEMBL255618 | 0.90 | PDE10A (0.38) | METFGFR3FGFR1FGFR2PDE10A | |
| SCHEMBL367900 | 0.90 | MET (0.39) | METFGFR3FGFR1FGFR2PDE10A | |
| SCHEMBL360828 | 0.90 | MET (0.39) | METPDE10AALDH1A1 | |
| SCHEMBL367903 | 0.90 | MET (0.40) | METFGFR3FGFR1FGFR2PDE10A | |
| Hydrochloric Acid SCHEMBL174468 | 0.90 | PDE10A (0.37) | METFGFR3FGFR1FGFR2PDE10A | |
| SCHEMBL10283532 | 0.89 | ALKBH1 (0.36) | METFGFR3FGFR1FGFR2PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130116231-A1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2013-05-09 | — | — | US | claimed |
| EP-2593107-A1 | TYROSINE KINASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2013-05-22 | — | — | EP | disclosed |
| US-20130116231-A1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2013-05-09 | — | — | US | disclosed |
| US-20130116231-A1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2013-05-09 | — | — | US | disclosed |
| US-20130116231-A1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2013-05-09 | — | — | US | disclosed |
| WO-2012009194-A1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2012-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116231-A1 | TYROSINE KINASE INHIBITORS | ABL1, ERBB2, MET | MET 3/4885FGFR3 199/4885FGFR1 58/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.